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Abstract
Since the introduction of Wireless Capsule Endoscopy (WCE) researchers have started exploring the design space of
Medical Capsule Robots (MCRs): embedded micro-systems that can operate autonomously within the human body and
can diagnose, prevent, monitor, and cure diseases. Although the research in the area of MCRs is an active topic and
has grown exponentially, current devices provide only limited functionalities because their design process is expensive
and time consuming. To open this research field to a wider community and, at the same time, create better designs
through advanced tool support, in our previous works we presented a design environment for the rapid development of
MCRs. In this paper, this environment was adopted to design a Drug Delivery Capsule (DDC) based on a coil-magnet-
piston mechanism. The force of the coil acting on the magnetic piston and the drug release profile were modeled and
assessed on bench-top with a maximum relative error below 5%. Then, in vivo trials were performed to validate the
DDC functionality with a scheduled drug release profile for a 5 hours and 24 minutes procedure. The resulting design
environment template is available open source for further development of drug delivery applications as well as to serve
as guideline in prototyping novel MCRs addressing other clinical needs.
Keywords: Surgical robotics, medical cyber-physical systems, drug delivery, medical capsule robots, design
environment, embedded micro-systems.
1. Introduction
The introduction in year 2000 of the PillCam by Given
Imaging [1] showed that embedded micro-systems can be
used to reach the more remote regions of the human Gastro-
intestinal (GI) tract. Since then, millions of patients have
swallowed this self-contained wireless camera to get a non
invasive diagnosis of diseases in the small intestine. Unfor-
tunately, this approach is not effective for other districts
of the GI tract, such as the colon and the stomach, where
more deadly forms of cancer usually develop [2]. The main
reason for this is related to the lack of advanced function-
alities, such as active locomotion [3], advanced diagnosis
and tissue manipulation [4], biopsy sampling [5], or drug
delivery [6].
In recent years, the research community has addressed
this issue by developing a number of robotic smart cap-
sules, referred in this paper as Medical Capsule Robot
(MCR). MCRs typically enter the human body through
natural orifices or small incisions and can perform en-
doscopy and surgery by interacting with the surrounding
environment with sensors and/or actuators.
∗Corresponding author, E-mail address:
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The design process of MCRs however is challenging
because it has to address severe cross-cutting constraints
such as size (to gain non invasive access, MCR diameter is
limited to about 1cm), power consumption (limited space
for battery is available onboard), and fail safe operation
(MCR operates deep inside the human body). Therefore,
MCR design and development requires significant skills
and efforts in embedded systems, miniaturized electron-
ics, packaging, debugging, and mechanical miniaturization
of the device. Custom circuit boards and mechanical en-
closures have to be engineered, which makes MCR devel-
opment an expensive and time consuming process that is
only accessible to a limited number of groups in the re-
search community [7].
Because many of the MCRs developed in the past share
equivalent hardware and software components such as spe-
cific sensors, data processing, actuation, and wireless com-
munication, we believe that it is indeed possible to system-
atize the design of MCRs. This would lower the barrier of
entry to this field to research groups that do not have the
resources to develop MCRs from the ground up.
In our previous works, we presented our contributions
towards the creation of an environment for the rapid design
and development of MCRs [7, 8, 9]. The basic elements
of the integrated design environment are shown in Fig. 1.
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Figure 1: The elements of the integrated design environment for
MCR.
At the time of writing, the design environment includes a
library of hardware modules built up from our experience
with existing capsule designs [10]. The hardware compo-
nents include fundamental elements of MCR design such
as sensors (inertial sensors, encoders, vital sign sensors),
actuators (DC motors, coils, illumination, servo motors,
stepper motors), batteries and voltage regulators, wireless
transceivers working at different carrier frequencies, and
microcontrollers (MCUs), which serve as building blocks
for the system. A flexible backbone enables plug-n-play
connectivity of up to six hardware modules. Each of the
hardware modules is coupled with a software component
and integrated in an open-source web environment avail-
able at pillforge.github.io for the developer to imple-
ment specific MCR applications.
In this work, we present how the design environment
can be adopted to develop a Drug Delivery Capsule (DDC)
based on a coil-magnet-piston mechanism for controlled
deployment of drug doses over time. As a result of this
work, we have created a design template for the DDC.
This template aims to provide MCR researchers a solu-
tion that shortens the development time of new DDCs
based on the same or a similar actuation principle. Tem-
plate parameters such as the drug viscosity and deploy-
ment schedules can be adjusted according the specifics of
the application. The force exerted by the coil-magnet-
piston mechanism and the drug release profile over time
have been modeled and characterized experimentally. Be-
yond the specific application of controlled drug delivery,
this work also illustrates how the open-source design envi-
ronment we have developed can be used to rapidly design
an MCR.
This paper is organized as follows: Section 2 briefly
presents the state of the art for drug delivery MCRs, Sec-
tion 3 illustrates the mechanical, electrical, and embedded
firmware and software design considerations for the devel-
oped MCR. This section also describes the design envi-
ronment and the design template that have been created
for the MCR. Section 4 presents the experimental assess-
ment on bench and in vivo results. Section 6 discusses
conclusions and future research directions.
2. Clinical Motivation for Drug Delivery Systems
The formulation of drugs that allow for reproducible
absorption profiles for targeting specific areas of the GI
tract represents a major bottleneck in current development
of orally administered medications [11]. This is mainly due
to unpredictable gastric transit time and physiochemical
characteristics of the GI tract that differ from patient to
patient [12].
The availability of a controllable Drug Delivery Sys-
tems (DDS) may reduce toxicity associated with systemic
administration and prevent the formation of antibodies to
drugs, particularly in the case of colon cancer or inflam-
matory bowel disease therapies [13]. These are two ex-
tremely common diseases, with colorectal cancer being the
second leading cause of cancer-related deaths in USA [14],
while Crohns disease and ulcerative colitis – both inflam-
matory bowel diseases – being diagnosed in 201 and 238
per 100,000 people in the USA, respectively.
Controllable MCRs targeting drug release have been
developed for therapeutic treatment of diseases in the GI
tract [6, 15] as well as for drug absorption studies [16]. Al-
though some devices are already commercially available,
such as the IntelliCap [17], the InteliSite [18], or the En-
terion capsule [19], they cannot implement an intelligent
release algorithm due to the lack of real-time localization
and active position control. Several MCRs have been pro-
posed to address these limitations. Yim et al. [20] de-
veloped a magnetic locomotion system that can collapse
under magnetic guidance and is able to deploy a liquid
drug. Kim et al. [21] proposed a three-axis Helmholtz coil
capsule which moves with a rotational motion and deploys
a drug. Woods et al. [22] integrated a holding mechanism
inside the capsule to resist to peristalsis and a needle for
local drug deployment. The MAARS capsule, presented
in [23], is composed of magnetic semi-hard modules and
deploys a single shot of drug upon a demagnetization pro-
cess. Yo et al. [24] recently proposed an MCR where the
drug release can be triggered through a reed switch. Fi-
nally, Hafezi et al. [25] developed an ingestible sensor that
allows patients, families, and physicians to monitor pre-
scription compliance and drug-adherence patterns in real
time.
While each of these capsules taken alone solves a spe-
cific problem, none of them offers a complete solution to
achieve an intelligent release of a drug on a specific target.
In order to do that, multiple functionalities need to be
combined and several design iterations need to be tested.
Thanks to the modular approach adopted in this work, we
have done a first step in that direction by implementing a
controllable mechanism for drug release and an intelligent
scheduler. These components take only part of the avail-
able slots on the flexible circuit backbone, leaving space
for adding other functional modules, such as localization
and/or active position control.
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3. Design Consideration
3.1. Principle of Operation - Mechanism Consideration
Referring to Fig. 2, where the principle of operation of
the MCR is presented, the DDC mechanism consists of a
drug chamber, two coils, and the magnetic piston. The
drug chamber (d = 7.94 mm, l = 6.35 mm, volume =
314.42 mm3) is hosted in a cylindrical enclosure together
with an axially magnetized cylindrical permanent magnet
acting as a piston (D54-N52, K&J Magnetics, USA). The
DDC shell and the drug chamber were prototyped with
an Objet30 3D printer (Stratasys, USA) with Vero white
material. The clearance between the outer diameter of the
magnetic piston and inner diameter of the chamber was 0.4
mm. This value guaranteed a low friction with the magnet,
resulting in no leakage of the drug and the actuating mech-
anism. The distal collar edge of the chamber has twelve
circular holes (each with a radius of rh = 0.8mm) from
where the drug is released into the environment. The num-
ber of holes and their radius have been chosen such that
the drug is deployed uniformly without being affected by
capillarity. In case the application requires a drug with
a different viscosity, the number of holes as well as their
dimension can be adjusted. The combination of proper
drug viscosity and aperture size prevents the drug from
leaking for any possible orientation of the capsule. Bench
trials showed that the proposed design is able to deploy
solutions with a viscosity up to 1000 cP, which is higher
than water (0.89 cP), blood (between 3 and 4 cP) and air
(0.018 cP).
To actuate the magnetic piston, two coils are mounted
at both sides of the drug chamber such that, when they are
activated, the current I induces two static magnetic fields
aligned along the same axis, having the same magnitude,
but opposite directions.
The force F (dz) induced by the two coils on the mag-
netic piston can be expressed as a function of the relative
position dz of the piston with respect to the two coils. The
trend of F (dz) was modeled with COMSOL multiphisics
(COMSOL Multiphysics, Stockholm, Sweden) and exper-
imentally verified as discussed in Section 4. Considering
the surface of the magnetic piston S, we can derive the
pressure P(dz) in the chamber as a function of the mag-
netic piston position dz :
P (dz) =
F (dz)
S
. (1)
Using the Hagen-Poiseuille’s equation [26], we can then
express the fluid flow V˙ as a function of the pressure as-
suming that the radius of the holes is smaller than their
length, the drug is a Newtonian fluid, and the motion of
the resulting drug flow across the holes is laminar. Under
these assumptions, we have:
V˙ = n ·
P (dz)
Rh
, (2)
Figure 2: Principle of operation of the DDC (a). When the coils are
activated (b) the magnetic piston deploys the drug outside of the
drug chamber.
where Rh =
8ρl
pir4
is the hydraulic resistance, ρ is the dy-
namic viscosity of the drug, while l, r and n are the length,
the radius and the number of holes in the chamber, respec-
tively.
From the flux V˙ , it is possible to derive the quantity
of drug released M as
M = V˙ · tact. (3)
with tact being the time period when the coil is active.
Coil Dimensioning. The magnetic force acting on the pis-
ton is proportional to the magnetic field B generated by
the coils as
F =
B2 ·A
µ
(4)
where F is the force, B is the magnetic field, A is the sec-
tion of the coil, and µ is the magnetic permeability of the
medium (i.e., air, therefore µ = µ0µr ≃ µ0). Since B is
a proportional to the current I, the coil dimensions, and
the number of turns, we need to optimize the three quan-
tities to achieve enough force to push the magnet along
the chamber against the drug.
On the other hand, the amount of current in the coil is
limited by the power dissipated by its internal resistance as
heat. For safety reasons, the capsule temperature should
not increase by more than 1oC [27]. Since the coils are
mounted in a parallel configuration, their total resistance
3
is RTC =
1
2
RC with RC resistance of a single coil. The
maximum current that can flow through the coil wire with-
out causing a 1oC increase is equal to 800 mA. Adopting a
value of 700 mA for the current, and considering that the
coil is supplied at 3.3 V, we have:
RTC =
V
I
=
3.3
0.7
= 4.71Ω (5)
thus RC = 9.42Ω for each coil. Since the wire resistivity
is ρ = 17.421 · 10−9Ωm and its is section Sw = 1.5386 ·
10−8m2, the length of the wire L results in:
L =
R · Sw
ρ
= 8.32m. (6)
Considering that the wire is wrapped around a circumfer-
ence of Cin = 0.0157m, the number of turns N results
in
N =
L
Cin
=
8.32
0.0157
= 530.394 ≈ 530 turns. (7)
Once wrapped, the coil results in a diameter of 10 mm, a
length of 18 mm, and an inductance of 1.5 mH.
3.2. Hardware Architecture
The hardware architecture for the presented MCR con-
sists of two separate systems: a base station and the DDC
itself. The base station [7] was used to exchange wireless
data between the MCR and the user interface. In this
particular application, the user might desire to change the
delivered therapy schedule after the capsule has been in-
gested, thus the base station is the only way to interact
with the DDC.
The DDC electronics consists of three embedded mod-
ules: the MCU, a 433 MHz transceiver, and the power-
ing and battery monitoring module. The modules, are
mounted on our flexible circuit. These components are
shown in Fig.3 before the flexible circuit is folded to fit
a capsule-shaped shell. The remaining three empty slots
on the flexible circuit can be used in the future to add
other functional modules. The MCU module is based on a
MSP430 (MSP430F5528, Texas Instruments, USA), which
communicates via Serial Peripheral Interface (SPI) with
the 433 MHz transceiver (CC1101, Texas Instruments, USA)
module. The driver for the coil actuation circuitry con-
sists of a power p-channel MOSFET (STR2P3LLH6, ST
Microelectronics, SUI), which has been mounted directly
on top of the flexible circuit. The two coils are connected
to the drain of the MOSFET. This module can provide up
to 800 mA. The MOSFET gate is driven by a MCU digi-
tal output with a Pulse Width Modulation (PWM) signal.
Finally, power to the DDC is provided by a 30 mA/h LiPo
rechargeable battery (LP-FR30, Plantraco LTD, USA).
Accordingly to the drug scheduler, the DDC deploys the
drug only at specific times. The battery lifetime therefore
has to be optimized to minimize the MCR power consump-
tion. This is achieved by running the MCU in low power
Figure 3: Picture of the embedded electronics of the DDC before
folding the flexible circuit. The lateral connectors at the opposite
sides of the flexible circuit are used for programming and debugging
the modules and are removed before integration into the capsule
shell.
mode, and activating its peripheral interfaces (e.g., wire-
less communication, actuation) on demand. Table 1 shows
the power consumption of the DDC embedded electronics
during different operating modes.
All the documentation related to the base station as
well to the other miniature hardware modules is available
at pillforge.github.io.
3.3. Design Environment & Scheduler
Developing an embedded application can be intimidat-
ing for novice users. Applications are usually coded with
low-level languages like C, which presents a barrier for re-
searchers whose expertise lies in the applications of MCR.
In addition, setting up tool chains and the necessary soft-
ware libraries for a specific target device is usually cum-
bersome. To alleviate these hardships, we have developed
a web-based visual software design environment [7].
The design environment provides a higher level of ab-
straction for applications, making it easier for developers
to reason about their software. A user can compile his/her
application through the design environment and download
its binaries through the web interface. Since the compila-
tion is processed on the server side, the user does not need
to install any additional tools.
We applied a proven model-based methodology [28] to
the MCR domain. This method allowed us to visually rep-
resent software models specific to MCR and to generate
the corresponding software artifacts. The compositional
features of model-based development’s provide additional
abstractions that can encapsulate the underlying complex-
ities. The design environment was implemented using the
Web-based Generic Modeling Environment (WebGME),
which is a modeling tool used to design domain-specific
visual modeling languages [29].
We have chosen TinyOS as the core operating sys-
tem for the MCR. TinyOS is an event-driven, operat-
ing system commonly used in small resource constrained
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Module Sleep Mode Idle Mode Tx or Rx Mode Drug Deployment
MCU 100 nA 1.8 mA 18.3 mA 32.5 mA
433MHZ transceiver 200 nA 8.4 mA 14.7 mA 14.7 mA
Power Board 8 µA 0.8 mA 0.8 mA 0.8 mA
Coil 0 A 0 A 0 A 700 mA
Total 8.3 µA 11 mA 33.8 mA 748 mA
Table 1: Power consumption of the embedded modules during the different modalities of operation of the DDC: sleep, idle, wireless trans-
mission or reception, deployment of the drug.
Figure 4: The design environment showing Base and MCR apps with the highlight of the schedule.
devices [30]. Its component based paradigm lends itself
naturally to the model-based methodology of our design
environment. Hence, a modeling language was created us-
ing WebGME to represent TinyOS language constructs.
A one to one mapping of TinyOS software components to
WebGME’s notion of components allows users to create
applications and visualize the interconnection and struc-
ture of the constituent software components. However,
this still requires users to implement their application logic
in TinyOS, which has a steep learning curve.
Instead, a higher level of abstraction is needed to con-
nect the users’ intentions to actual TinyOS components.
To this end, we have added blocks to our previous [8] meta
language definition of TinyOS to support a higher level of
abstraction. Blocks are WebGME components that expose
customizable inputs, outputs, and parameters to users.
They also abstract data types and allow users to visu-
ally connect data to the apps without writing any textual
code.
In this work, we have created two template apps that
can be used in the DDS, which is composed of the base
station and the MCR. The corresponding software models
can be seen in figure 4. For the base station, the sched-
ule and viscosity blocks are connected to a template drug
delivery base app, while the heartbeat rate value block is
connected to a template drug delivery MCR app’s port.
MCR sends a status message periodically to the base sta-
tion. The status messages used for the communication
protocol between MCR and the base station as well as to
signal to the base station that the MCR is still alive (hence
the name heartbeat). Once the communication is estab-
lished between the devices, the remaining percentage of
drug is used as the payload in the status messages. The
heartbeat rate value determines the frequency of messages
5
Figure 5: The experimental setup to assess the force F(dz) inside the
drug chamber while the coils are active.
send from the MCR. In addition, the template apps have
attributes to set the radio address for wireless communi-
cation.
The internal structure of the schedule block can be seen
in Fig. 4. The blue object represents the beginning of a
schedule, the green elements represents the amount of drug
to be released. Blue and green elements are connected
with time connections. The schedule block dictates what
percentage of drug should be released in the specified time
intervals.
Once the schedule and the parameters are set, a user
can compile the application by running the compiler plu-
gin via the arrow button located on top left of the de-
sign environment. The generator traverses the input data
and feeds it to the template app. The app gets com-
piled on the server side, the resulting binaries, in turn,
can be downloaded by the user. The software is available
at https://github.com/pillforge/drug.delivery.
4. Device experimental assessment
Experimental trials aimed to assess and characterize
the DDC functionality were performed. The interaction
force exerted from the two coils on the magnetic piston
was modeled and experimentally validated. We also ver-
ified that the DDC, once programmed with a scheduler,
delivered the amount of drug expected from the release
profile described in Section 3.1. Finally, the reliability and
Figure 6: Experimental data measured from the load cell compared
to the finite element analysis simulation.
functionality of the device were tested in an in vivo trials
on a canine model.
4.1. Validation of the interaction force between the coils
and the magnet
The interaction force between the coils and the mag-
net has been modeled using finite element analysis (COM-
SOL) by assuming the two coils as Helmholtz coils with
the following geometrical and electrical parameters: num-
ber of turns N = 531, resistivity of the wire ρ = 17.421 ·
10−9 Ωm2, radius of the coil rc = 2.5 mm, current flow-
ing in each coil Ic = 350mA, diameter of the wire dw =
0.2 mm, and length of the coil L = 1 cm. The motion
of the magnetic piston occurs along the z direction of the
DDC, thus we extracted from the simulation the numer-
ical values for the interacting force F(dz) as a function
of the piston position into the drug chamber. The same
quantity was then experimentally measured with the setup
presented in Fig. 5. A rapid prototyping part (Objet
30, Objet Geometries Ltd, USA) was designed to mount
a 3-axis force sensor (NANO17, ATI Industrial Automa-
tion, USA) with the coils and the drug chamber. Opposite
to the chamber, the magnetic piston was mounted at the
end effector of a six-degree-of-freedom robotic manipulator
(RV6SDL, Mitsubishi Corp., Japan). While the coils were
active, the magnetic piston was moved inside the chamber
for its entire length, while the resulting force was collected
using a Universal (Serial Bus (USB) data acquisition board
(NI-PCI 6224, National Instruments, USA) at a sampling
rate of 100 Hz.
The graph of the modeled force and the experimental
data are represented in Fig. 6. The plot shows a parabolic
and symmetric trend for the force, which reaches its min-
imum exactly at the center of the chamber, halfway be-
tween the coils. The relative error between the finite ele-
ment simulation and the force sensor data was 3.4%(σ =
±2.5mN).
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In order to validate the effect of gravity on the drug de-
livery mechanism, the trials were performed with the cap-
sule assuming different orientations. Since the contribute
of gravitational force is negligible compared to the mag-
netic force generated by the coil, the mechanism was able
to withstand it regardless of the capsule orientation.
4.2. Validation of the drug released
This trail aimed to verify the ability of the DDC to
release a scheduled quantity of drug with time. In Sec.
3.1 we derived expressed the quantity of drug released M
as a function of the flux V and the time of activation of
the coils. This relationship was verified on bench with in
this experimental setup.
Figure 7: Predicted drug delivery profile (in blue) compared with
the experimental data (in red) for one of the trial.
The capsule drug chamber was filled with a solution
of 40% water and 60% lubricant, resulting in a dynamic
viscosity of 0.032 Pa · sec and with a solution of 50% wa-
ter and 50% lubricant, resulting in a dynamic viscosity of
0.024 Pa · sec. The MCU was programmed to deliver a
scheduled quantity of solution every 7 minutes and thirty
seconds accordingly to the scheduler profile. Every time
that the drug release was triggered, the MCR was placed
on a digital scale (American Weigh Scales, Inc, USA, reso-
lution 0.01± 0.005g) and its weight recorded. The quantity
of solution released with time was thus derived from the
capsule initial weight, when the drug chamber was com-
pletely filled up. Ten different experimental trials were
then performed. The results of one of the trial for the two
different viscosity is shown in Fig. 7, where the expected
drug deployment profile (in blue) is compared to the ac-
tual experimental profile data (in red). Repeatability tests
for delivering 10% of the drug loaded into the chamber re-
sulted in an average drug aliquot of 72 µL with a standard
deviation of 0.28 µL.
A good matching of the experimental data with the
expected drug release profile was observed. Overall, the
relative error for the quantity of drug released vs. its ex-
pectation is 2.4% ± 1.8%. Current consumption of the
device matched the values reported in Table 1 with a rel-
ative error equal to 3%. In particular, the current in the
coil was 695 mA.
4.3. In Vivo Trial
The in vivo trial was performed at Vanderbilt Univer-
sity under protocol M/14/014, that included other devices
and experiments, using a 25 kg female dog under general
anesthesia. The DDC drug chamber was filled with a so-
lution of 60% water and 40% lubricant with a green dye,
resulting in a dynamic viscosity of 0.05 Pa · sec. The cap-
sule was then programmed to schedule a drug delivery of
7 µL every 15 s until all the drug in the chamber was
completely deployed for a total of 6 doses.
The DDC was inserted from the anus into the colon us-
ing a standard colonscope and left in place for the amount
of time needed for the trial. The same colonscope was used
to observe the release of the drug under insuﬄation of the
colon. Figure 8 shows the sequence of the DDC deploying
a scheduled drug doses: the drug release is first triggered
(A), then the drug starts to flow outside of the chamber
(B) and reaches the colon tissue (C).
The current consumption of the DDC during the trial
was estimated as in [31] using the following average current
consumptions:
I =
∑
i IiTi∑
i Ti
, (8)
where Ii and Ti are the current consumption from Tab.
1 and the time interval related to a single action performed
by the DDC, respectively. For our particular application
I resulted equal to 28 mA. Adopting a battery with a ca-
pacity of 250 mAh, we can expect a maximum lifetime of
T = 250
28
≅ 8h and 50 min. The in vivo trial showed that
the device was able to operate for at least 5 hours and
24 minutes. After that, all the drug was deployed and the
trial was considered as concluded. In case that a longer op-
erating time were needed, battery lifetime can be further
extended by increasing the MCU sleep intervals. Crohn’s
disease and ulcerative colitis are inflammatory small bowel
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Figure 8: A sequence from the in vivo trials. The drug deployment is triggered (A), the drug release starts (B), and the dose reaches the
colon tissue (C).
diseases that are typically treated by releasing controlled
quantities of drugs over a period of time. While the typ-
ical transit time for 50% of food in the small bowel is up
to three hours, human clinical trials in this GI tract for
similar MCR, (e.g. the Intellicap) have shown an average
small bowel transit of up to 5 hours. The actual battery
lifetime guarantees enough time for the device to operate
while traveling across the small bowel. However, since the
delivery time and the quantity of drug deployed can be
adjusted with the scheduler, different diseases can be tar-
geted. The purpose of the animal trial was to qualitatively
assess the functionality of the DDC in a clinical scenario.
The main limitation of the trial compared to a clinical
scenario was that the device was not swallowed, because
of the protocol trial time. The goal of the trials was to
assess if the device was able to properly operate inside a
constrained environment, being able to respond to wire-
less commands, and reliably actuate the mechanism. For
this purpose, we first tried the device without insuﬄation.
After the scheduled time of drug delivery, we insuﬄated
the colon and we checked proper deployment of the drug.
At this point, we run a trial with insuﬄation to capture a
video footage.
5. Discussion
As discussed in [7], the main purpose of our modular
design environment is to accelerate the time-to-prototype
for the early validation of design hypothesis in the field of
MCRs. The time-to-prototype depends principally on the
complexity of the hardware and software of the MCR as
well as the skill-set and experience of the developer.
In particular, hardware complexity consists of circuit
design, assembly of miniature components, and testing.
While a custom approach requires the developer to go
through these iterative steps until the desired level of minia-
turization and performance is achieved, our modular de-
sign environment provides the user with miniaturized hard-
ware modules and a flexible circuit for easier connectiv-
ity. The same degree of miniaturized connectivity can be
achieved in custom designs with flexible PCB cables or
hybrid PCB solutions, but they are known to be expen-
sive for the low volumes that are typical for research and
proof-of-concept validation [32].
Software complexity consists of writing efficient embed-
ded C code to implement the various functions of an MCR
and to communicate with external components such as
sensors, actuators and wireless base stations. Instead, our
modular design environment provides the developer with
a set of software components, which can be customized ac-
cording to the requirements of the application. Ultimately,
the experience and skill-set of the developers involved de-
termines how efficiently the described hardware and soft-
ware complexities are managed. Exact quantitative bene-
fits of our component based design further depend on the
specifics of the application, however, to give to the reader
an idea of the time and cost outcomes, the swimming cap-
sule MCR described in [7], has been developed and assem-
bled in less than two months with an overall estimated cost
of 15,000 USD (including materials and support for per-
sonnel) compared to nine months and an estimated cost
of 50,000 USD for the MCR presented in [33].
It is worth mentioning that the hardware platform we
propose, being a system made of modules, is not opti-
mized for any particular application. Thus, MCRs built
with our platform are generally larger than their custom
counterparts, as shown in Fig. 3 compared to Fig. 9.
6. Conclusions
In this work, we presented a component based design
of a DDC robot based on a coil-magnet-piston mechanism.
This device aims to provide a controlled deployment of
drug doses over time with a scheduler. The drug viscosity
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Figure 9: a) A picture of the final DDC prototype, where the embedded electronics was developed via custom design. The device is 25 mm
long for a diameter of 16 mm. b) The drug stars to be released and c) is completely deployed.
and deployment time can be set in the application tem-
plate for the design environment according to the desired
drug release profile. The magnetic force as well as the drug
release profile have been modeled and then experimentally
verified. The models for the force and the released drug
profile showed relative errors below 5% when compared to
the experimental data. The functionality of the DDC was
also successfully assessed in a clinical scenario via an in
vivo trial.
In this work, we validated the hypothesis that a coil-
magnet-piston mechanism is a viable solution for a sched-
uled drug release. However, the DDC that we developed
by assembling the preexisting modules from our library re-
sulted in a size that is impossible to swallow. Therefore,
once we were confident with the coil-magnet-piston mecha-
nism operation, we scaled down our design to an ingestible
size by designing a custom flexible circuit. The DDC rep-
resented in Fig. 9 is 16 mm in diameter and 25 mm in
length with a drug reservoir of 201.06 mm3. This capsule
contains a scaled version of the coil-magnet-piston mecha-
nism described in this paper and it is capable of deploying
drugs with viscosities up to 700 cP. The DDC weight was
decreased from 18 g to 12 g, while power consumption in
the Tx or Rx mode and in the Drug Deployment mode
were reduced from 33.8 mA to 24.2 mA and from 748 mA
to 418 mA, respectively.
Beyond the specific design, modeling, and assessment
of the proposed coil-magnet-piston mechanism, the main
contribution of this work is to illustrate how our compo-
nent based design environment can be leveraged for the
early validation of a novel MCR design. All the hard-
ware and software components described in this paper are
available open-source at pillforge.github.io and can
be used as a template by the MCR research community.
Future work aims to expand the DDC template with
modules for magnetic locomotion [3], anchoring for local-
ized drug delivery, and magnetic localization [34] toward
the end goal of intelligent drug delivery in the GI tract.
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